Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985464 | 0.79 | P2RX7 (0.41) | PDE9A | |
| SCHEMBL985375 | 0.79 | CNR2 (0.35) | CNR2CNR1ESR1PTPN11 | |
| SCHEMBL985813 | 0.63 | IDO1 (0.32) | CNR2 | |
| SCHEMBL984931 | 0.62 | HSP90AA1 (0.33) | CNR2 | |
| SCHEMBL4661476 | 0.62 | IDO1 (0.40) | CNR2CNR1PTPN11 | |
| SCHEMBL1645046 | 0.62 | CYP4F2 (0.39) | CNR2PTPN11S1PR1 | |
| SCHEMBL28987256 | 0.61 | OPRK1 (0.36) | PDE9A | |
| SCHEMBL986393 | 0.61 | RXRA (0.35) | CNR2PTPN11 | |
| SCHEMBL984877 | 0.60 | HCAR1 (0.34) | — | |
| SCHEMBL20399577 | 0.59 | PTPN11 (0.40) | PTPN11S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | CNR2 3266/4885CNR1 3027/4885ESR1 2111/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | CNR2 3266/4885CNR1 3027/4885ESR1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.